North America Menopause Market Outlook, 2030

2025

North America Menopause Market Outlook, 2030

The North America Menopause Market is segmented into By Treatment (Dietary Supplements, OTC Pharma Products), By Stages (Menopause, Pre-Menopause, Post-Menopause), By Route of Administration (Oral, Transdermal, Injectable, Vaginal), By End User (Hospital, Diagnostic Centers, Specialty Clinics, Other End Users), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others).

Bonafide Research
17-08-2025
Pages : 91
Figures : 9
Tables : 20
Region : North America
Category : Lifescience & Healthcare
Healthcare

Schedule a Call

Buy Now Get Free sample

North America menopause market to grow 5.33% CAGR (2025–30), with hormonal therapies remaining the most preferred treatment option.

Historical Period2019-2023
Base Year2024
Forecast Period2025-2030
CAGR (2025-2030) 5.33%
Largest MarketUnited States
Fastest Market Canada
Format

Featured Companies

1. Bayer AG
2. Dr. Reddy’s Laboratories Limited
3. Pfizer Inc.
4. Novo Nordisk A/S
5. DSM-Firmenich AG
6. Roche Holding AG
More...

Highend Report

Highend report of this product is available

View

New Report Guarantee

If you purchase this report now and we update it in next 100 days, get it free!

Menopause Market Analysis

In North America, menopause care has shifted from a quiet, often misunderstood topic to a visible public health priority, driven by growing recognition of its prevalence and impact on women’s lives. Menopause, defined as the absence of menstrual periods for 12 consecutive months, occurs on average at age 51 in the US and 52 in Canada, following a perimenopausal transition that may last up to eight years, in both countries, this shift is affecting millions, with over 10 million Canadian women over 40 and an estimated 1.3 million US women entering menopause annually. Despite its inevitability, awareness remains uneven surveys show that 46% of Canadian women feel unprepared for menopause, 60% do not associate symptoms like depression or joint pain with the hormonal transition, and 41% of Canadian medical schools omit menopause from formal curricula, contributing to knowledge gaps among clinicians. According to the CDC and Health Canada, the most reported symptoms in North America include hot flashes affecting up to 80% of women, joint discomfort, vaginal dryness, mood swings, and sleep disturbance, with symptom severity often linked to lifestyle factors such as obesity, stress, and poor diet issues more prevalent in urbanized, high-stress North American environments. Gynecologists and endocrinologists lead complex cases, while general practitioners serve as first-line providers, though fewer than 20% in the US follow the latest menopausal hormone therapy (MHT) guidelines from NAMS, WHO, or EMAS, which now emphasize balanced risk-benefit discussions and expand non-hormonal options like cognitive behavioral therapy for vasomotor symptoms. Digital health is reshaping access through AI-driven symptom trackers, wearable sensors, and telemedicine services such as Nyah Health, enabling more women to receive tailored menopause care regardless of geography. IQVIA tracking over 40 active clinical trials targeting vasomotor symptoms, bone density loss, and mood disorders, many funded by leading pharma such as Pfizer, Astellas, and Bayer. According to the research report "North America Menopause Market Outlook, 2030," published by Bonafide Research, the North America Menopause market is anticipated to grow at more than 5.33% CAGR from 2025 to 2030. Hormonal therapies remain the most prescribed option, with US CDC and NAMS data indicating that 15–20% of menopausal women currently use menopausal hormone therapy (MHT), though uptake varies due to safety concerns following past WHI study findings. In parallel, non-hormonal pharmaceuticals such as SSRIs, SNRIs, and gabapentin are gaining traction, particularly among women with contraindications to estrogen therapy, while dietary supplements and botanical formulations are surging in popularity black cohosh, soy isoflavones, and flaxseed-based products lead sales in both the US and Canada. Telehealth has become a defining access channel, with platforms like Midi Health and Alloy Women’s Health reporting year-on-year growth in virtual consultations for menopause care, extending reach into rural communities underserved by specialist clinics. FDA approvals and Health Canada product authorizations shape the market pipeline, with recent clearances for low-dose vaginal estrogen creams, novel transdermal estradiol sprays, and fezolinetant, a first-in-class neurokinin-3 receptor antagonist for hot flash management. Retail pharmacies, including CVS, Walgreens, Shoppers Drug Mart, and Rexall, dominate product distribution in urban areas, while online pharmacies like Well.ca and Amazon Canada are expanding category listings for both OTC and prescription menopause products, often bundled with subscription-based wellness programs. The WHO’s Healthy Ageing initiative and NAMS educational campaigns are indirectly influencing regional adoption by promoting early intervention and symptom tracking. Employer-driven wellness programs are increasingly relevant, with North American surveys showing that nearly 30% of large companies now offer menopause-related benefits, including subsidized therapy and flexible schedules, to improve retention.

to Download this information in a PDF

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

Market Dynamic

Market Drivers

• High Awareness and Health Literacy: North America has strong awareness of menopause as a key women’s health issue. Women and healthcare providers are well-informed about symptoms and treatment options due to widespread education campaigns and research. This understanding drives higher demand for hormone therapy and non-hormonal treatments. Advanced healthcare infrastructure and insurance coverage also support access to specialized menopause care, increasing market growth in this region. • Advances in Hormone Therapy and Digital Tools: The region benefits from continuous innovation in hormone replacement therapies that improve safety and efficacy. Additionally, digital health platforms and telemedicine services enable personalized symptom tracking and remote consultations. These advancements expand treatment accessibility and patient engagement, fueling growth in menopause care adoption across North America.

Market Challenges

• Concerns Over Hormone Therapy Safety: Despite medical advances, some women remain hesitant to use hormone therapy due to past studies linking it to cancer risks. This fear limits the adoption of effective treatments and pushes patients towards less proven alternatives. Educating patients and providers about the safety profiles of modern therapies remains a challenge. • Unequal Access in Rural and Low-Income Areas: Although urban centers offer comprehensive menopause care, rural and economically disadvantaged populations often lack specialized services. Limited healthcare provider availability and digital connectivity gaps restrict access to both diagnosis and treatment, creating disparities within the region.

Market Trends

• Expansion of Telemedicine for Menopause Care: Telehealth adoption has surged, allowing women to consult specialists remotely. Platforms provide symptom monitoring, education, and treatment management, particularly benefiting those with mobility or geographic barriers. This trend increases convenience and reduces stigma associated with menopause discussions. • Growth in Natural and Non-Hormonal Treatments: There is rising consumer interest in plant-based supplements and non-hormonal therapies as alternatives to traditional hormone replacement. Products containing phytoestrogens and other natural ingredients are gaining market share, driven by safety concerns and preferences for holistic health approaches.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Menopause Segmentation

By Treatment	Dietary Supplements
	OTC pharma products
By Stages	Menopause
	Pre-menopause
	Post-menopause
By Route of Administration	Oral
	Transdermal
	Injectable
	Vaginal
By End User	Hospital
	Diagnostic Centers
	Specialty Clinics
	Other End Users
By Distribution Channels	Hospital Pharmacy
	Retail Pharmacy
	Online Pharmacy
	Others
North America	United States
	Canada
	Mexico

Dietary supplements are the largest and fastest-growing treatment segment in the North America menopause market because of their widespread consumer acceptance, easy accessibility, and preference for natural and non-hormonal options among menopausal women. In North America, the popularity of dietary supplements for managing menopause symptoms has surged as many women seek alternatives to traditional hormone therapies due to concerns about side effects and health risks. These supplements offer a perception of being safer and more natural, appealing to women who prefer to avoid pharmaceuticals. The market benefits from a well-established retail and e-commerce infrastructure, making supplements readily available in pharmacies, health stores, and online platforms, which increases convenience for consumers. The presence of a wide variety of supplements including vitamins, minerals, herbal extracts like black cohosh and soy isoflavones, and other botanicals caters to diverse preferences and symptom relief needs. Health trends emphasizing wellness and holistic care further drive the demand for these products as part of lifestyle management. Additionally, many supplements are marketed directly to consumers with clear labeling and claims supported by some scientific studies, helping build trust and encouraging self-care. The growth is also supported by rising awareness through social media, influencer endorsements, and health education campaigns that promote the benefits of supplements for bone health, hot flashes, mood stability, and overall well-being. Healthcare providers sometimes recommend supplements as part of an integrated approach when hormone therapy is not suitable or preferred. The regulatory environment in the US, though strict about safety, allows supplements to be sold without prescription, reducing barriers to access. Menopause is the largest and fastest-growing stage in the North America menopause market because it represents the period when most women experience significant symptoms that require medical intervention and treatment. In North America, the menopausal stage marks the transition during which women face a sharp decline in estrogen levels, leading to a range of physical and emotional symptoms such as hot flashes, night sweats, mood swings, and sleep disturbances. These symptoms can substantially impact daily life and work productivity, prompting many women to seek effective treatment options. Increased awareness about menopause and its effects, driven by public health campaigns and better education among healthcare providers, has encouraged women to address symptoms rather than ignore them. Advances in medical research have also led to the availability of diverse treatment options, including hormonal therapies, non-hormonal drugs, and dietary supplements, which are particularly targeted during this stage. Additionally, the menopausal period is often when women are most engaged with healthcare systems, leading to higher diagnosis and treatment rates. The integration of digital health tools such as symptom tracking apps and telemedicine consultations has made it easier for women to access care during menopause, increasing market demand. Women in North America also benefit from health insurance policies that often cover menopause-related treatments, further facilitating access. The combination of symptom severity, heightened health awareness, evolving treatment technologies, and improved healthcare access all contribute to menopause being the largest and fastest-growing stage in the North American market. This period serves as the critical window for intervention and management, which drives substantial market activity and innovation aimed at improving women’s quality of life during this phase. Transdermal administration is the fastest-growing route in the North America menopause market because it offers effective hormone delivery with fewer side effects and greater patient convenience compared to oral therapies. In North America, transdermal delivery systems such as patches, gels, and sprays have gained rapid acceptance due to their ability to provide steady hormone levels directly through the skin, bypassing the digestive system. This method reduces the risk of liver metabolism and blood clot formation, concerns often associated with oral hormone replacement therapy. Studies have shown that transdermal estrogen leads to lower incidences of adverse cardiovascular events and stroke compared to oral routes, making it a safer alternative for many women. Additionally, transdermal products offer ease of use and flexible dosing, allowing women to adjust therapy based on symptom severity and personal preference. The non-invasive nature of patches and gels also appeals to women who want to avoid daily pills or injections. The rise of personalized medicine and patient-centric care models has pushed healthcare providers in the U.S. and Canada to recommend transdermal options more frequently, supported by clinical guidelines from bodies like the North American Menopause Society. Furthermore, insurance coverage and growing awareness about the benefits of transdermal therapy have made these products more accessible. In addition, advances in transdermal technology have improved skin absorption and minimized irritation, enhancing patient comfort and satisfaction. The growing number of telehealth consultations in North America has also facilitated easier prescription and management of transdermal therapies. Women living in remote or underserved areas benefit from these convenient delivery methods without frequent clinic visits. The main reason hospitals are the largest end users is their ability to provide comprehensive, multidisciplinary care combined with advanced diagnostic and treatment facilities. Hospitals in North America serve as the primary healthcare providers offering a wide range of services essential for menopause management. They bring together specialists such as gynecologists, endocrinologists, and primary care physicians who collaborate to diagnose and treat menopausal symptoms effectively. Hospitals provide access to various treatment options, including hormone replacement therapy, non-hormonal medications, and support for related health issues such as osteoporosis and cardiovascular risks. These settings also have well-equipped diagnostic labs and imaging centers, allowing quick assessments like bone density scans or hormone level tests that are critical for personalized treatment plans. Many women with complex symptoms or multiple health conditions prefer hospitals due to the availability of round-the-clock care and continuous monitoring. Additionally, insurance coverage in North America often favors hospital-based treatment, making these facilities more affordable for many patients. Hospitals also conduct clinical trials and adopt new therapies early, attracting patients seeking advanced care. Public health initiatives often use hospitals as centers for awareness and education on menopause, increasing patient inflow. The trust associated with hospitals, combined with their integrated services and strong insurance linkages, makes them the largest and most preferred end users in the North American menopause market. Hospitals also offer integrated support services like nutrition counseling and mental health care, which are vital for managing menopause holistically. Their established reputation and trust among patients further reinforce their position as the preferred choice for menopause treatment in North America. The main reason online pharmacies are the fastest-growing channel is their convenience and accessibility, which meet modern consumers’ demand for easy, private, and quick access to menopause treatments. Online pharmacies have surged in popularity across North America by offering women a hassle-free way to obtain menopause-related products, including hormone replacement therapies and dietary supplements, without needing to visit physical stores or clinics. This channel allows for 24/7 ordering, direct-to-door delivery, and discreet packaging, addressing privacy concerns many women have when seeking treatment for menopause. The integration of telemedicine with online pharmacies enables patients to get prescriptions renewed or changed remotely, streamlining the treatment process. Subscription services and automatic refills help ensure better treatment adherence, a key factor in managing menopausal symptoms effectively. The COVID-19 pandemic accelerated the use of digital health platforms, creating lasting shifts toward online medication purchases. Online pharmacies also provide detailed product information, reviews, and personalized recommendations, helping consumers make informed decisions independently. This model is especially valuable for women in rural or underserved areas who face difficulties accessing traditional pharmacies or healthcare providers. Insurance compatibility and easy digital payment options further enhance the appeal of online pharmacies. Moreover, partnerships between online pharmacies and healthcare providers have improved the reliability and safety of medications offered through these platforms. Continuous advancements in digital security also build consumer trust, making online pharmacies a fast-growing and convenient distribution channel for menopause care in North America.

to Download this information in a PDF

Menopause Market Regional Insights

The USA leads the North America menopause market primarily because of its advanced healthcare infrastructure, high research investment, and widespread access to innovative menopause therapies. The leadership of the USA in the North American menopause market is the result of multiple factors working together to create an environment that supports comprehensive care for menopausal women. The country has a highly developed healthcare system that combines cutting-edge medical technology with extensive healthcare services, allowing women to access a broad range of treatment options including hormone replacement therapy and newer non-hormonal drugs. Strong investment in research and development by both public and private sectors fuels continuous innovation, leading to the introduction of advanced therapies that address symptoms more effectively. Additionally, the USA benefits from significant health insurance coverage, both public and private, which helps reduce the financial burden for many women seeking treatment. Healthcare providers in the USA tend to have specialized training in menopause management, improving diagnosis rates and personalized care approaches. The cultural climate also plays an important role, with greater awareness and openness around menopause issues compared to other countries. This reduces stigma and encourages women to seek professional support early, enhancing treatment outcomes. The rise of digital health platforms and telemedicine has further expanded access, especially for those in rural or underserved areas, enabling continuous care without geographical limitations. Furthermore, the USA hosts many leading pharmaceutical companies and research institutions that conduct clinical trials and develop new menopause-related products, maintaining the country’s position as a hub for innovation in this field. Public health initiatives and advocacy groups actively work to increase education and awareness, creating a more informed population that demands better care.

to Download this information in a PDF

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

Companies Mentioned

Bayer AG
Dr. Reddy’s Laboratories Limited
Pfizer Inc.
Novo Nordisk A/S
DSM-Firmenich AG
Roche Holding AG
Besins Healthcare
Pure Encapsulations, LLC
Gennev
Evernow
Kindra
Elektra Health

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Supply chain Analysis
2.5. Policy & Regulatory Framework
2.6. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. North America Menopause Market Outlook
6.1. Market Size By Value
6.2. Market Share By Country
6.3. Market Size and Forecast, By Treatment
6.4. Market Size and Forecast, By Stages
6.5. Market Size and Forecast, By Route of Administration
6.6. Market Size and Forecast, By End User
6.7. Market Size and Forecast, By Distribution Channels
6.8. United States Menopause Market Outlook
6.8.1. Market Size by Value
6.8.2. Market Size and Forecast By Treatment
6.8.3. Market Size and Forecast By Stages
6.8.4. Market Size and Forecast By Distribution Channels
6.9. Canada Menopause Market Outlook
6.9.1. Market Size by Value
6.9.2. Market Size and Forecast By Treatment
6.9.3. Market Size and Forecast By Stages
6.9.4. Market Size and Forecast By Distribution Channels
6.10. Mexico Menopause Market Outlook
6.10.1. Market Size by Value
6.10.2. Market Size and Forecast By Treatment
6.10.3. Market Size and Forecast By Stages
6.10.4. Market Size and Forecast By Distribution Channels
7. Competitive Landscape
7.1. Competitive Dashboard
7.2. Business Strategies Adopted by Key Players
7.3. Key Players Market Positioning Matrix
7.4. Porter's Five Forces
7.5. Company Profile
7.5.1. Bayer AG
7.5.1.1. Company Snapshot
7.5.1.2. Company Overview
7.5.1.3. Financial Highlights
7.5.1.4. Geographic Insights
7.5.1.5. Business Segment & Performance
7.5.1.6. Product Portfolio
7.5.1.7. Key Executives
7.5.1.8. Strategic Moves & Developments
7.5.2. Pfizer Inc.
7.5.3. Besins Healthcare
7.5.4. Novo Nordisk A/S
7.5.5. Roche Holding AG
7.5.6. DSM-Firmenich AG
7.5.7. Pure Encapsulations, LLC
7.5.8. Gennev
7.5.9. Dr. Reddy’s Laboratories Ltd.
7.5.10. Evernow
7.5.11. Kindra
7.5.12. Elektra Health
8. Strategic Recommendations
9. Annexure
9.1. FAQ`s
9.2. Notes
9.3. Related Reports
10. Disclaimer

Table 1: Global Menopause Market Snapshot, By Segmentation (2024 & 2030) (in USD Billion)
Table 2: Influencing Factors for Menopause Market, 2024
Table 3: Top 10 Counties Economic Snapshot 2022
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: North America Menopause Market Size and Forecast, By Treatment (2019 to 2030F) (In USD Billion)
Table 7: North America Menopause Market Size and Forecast, By Stages (2019 to 2030F) (In USD Billion)
Table 8: North America Menopause Market Size and Forecast, By Route of Administration (2019 to 2030F) (In USD Billion)
Table 9: North America Menopause Market Size and Forecast, By End User (2019 to 2030F) (In USD Billion)
Table 10: North America Menopause Market Size and Forecast, By Distribution Channels (2019 to 2030F) (In USD Billion)
Table 11: United States Menopause Market Size and Forecast By Treatment (2019 to 2030F) (In USD Billion)
Table 12: United States Menopause Market Size and Forecast By Stages (2019 to 2030F) (In USD Billion)
Table 13: United States Menopause Market Size and Forecast By Distribution Channels (2019 to 2030F) (In USD Billion)
Table 14: Canada Menopause Market Size and Forecast By Treatment (2019 to 2030F) (In USD Billion)
Table 15: Canada Menopause Market Size and Forecast By Stages (2019 to 2030F) (In USD Billion)
Table 16: Canada Menopause Market Size and Forecast By Distribution Channels (2019 to 2030F) (In USD Billion)
Table 17: Mexico Menopause Market Size and Forecast By Treatment (2019 to 2030F) (In USD Billion)
Table 18: Mexico Menopause Market Size and Forecast By Stages (2019 to 2030F) (In USD Billion)
Table 19: Mexico Menopause Market Size and Forecast By Distribution Channels (2019 to 2030F) (In USD Billion)
Table 20: Competitive Dashboard of top 5 players, 2024

Figure 1: Global Menopause Market Size (USD Billion) By Region, 2024 & 2030
Figure 2: Market attractiveness Index, By Region 2030
Figure 3: Market attractiveness Index, By Segment 2030
Figure 4: North America Menopause Market Size By Value (2019, 2024 & 2030F) (in USD Billion)
Figure 5: North America Menopause Market Share By Country (2024)
Figure 6: US Menopause Market Size By Value (2019, 2024 & 2030F) (in USD Billion)
Figure 7: Canada Menopause Market Size By Value (2019, 2024 & 2030F) (in USD Billion)
Figure 8: Mexico Menopause Market Size By Value (2019, 2024 & 2030F) (in USD Billion)
Figure 9: Porter's Five Forces of Global Menopause Market

Menopause Market Research FAQs

Hormonal therapies remain the most prescribed despite varying uptake.

SSRIs, SNRIs, gabapentin, and dietary supplements like black cohosh and soy isoflavones.

Health Canada authorizes products like low-dose estrogen creams and sprays.

Perimenopause is the transitional phase before menopause and can last up to 8 years.

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted